Literature DB >> 30140701

Genetic Variant rs755622 Regulates Expression of the Multiple Sclerosis Severity Modifier D-Dopachrome Tautomerase in a Sex-Specific Way.

Zhijie Han1, Jiaojiao Qu2, Jiehong Zhao3, Xiao Zou2.   

Abstract

Multiple sclerosis (MS) is a sex-specific autoimmune disease involving central nervous system. Previous studies determined that macrophage migration inhibitory factor (MIF) and its homologue D-dopachrome tautomerase (DDT) sex-specifically affect MS progression. Moreover, other studies reported that rs755622 polymorphism in promoter region of MIF gene is associated with risk of MS and affects the promoter activity to regulate MIF expression in a sex-specific way. Given that MIF and DDT share a part of promoter sequence, we surmise that rs755622 can also regulate DDT expression in a sex-specific way. However, this has not yet been studied. Here, we used five large-scale expression quantitative trait loci (eQTLs) and two RNA-seq datasets from brain and blood to assess the potential influence of rs755622 variant on expression of DDT in different genders by the linear regression and differential expression analysis. The results show that the minor allele frequency of rs755622 and expression of DDT are significantly increased in males for MS subjects and this minor allele variant can significantly upregulate DDT expression for males but not females, which suggests that the regulation of DDT expression level by rs755622 can affect MS progression in males. These findings further support and expand conclusions of previous studies and may help to better understand the mechanisms of MS.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30140701      PMCID: PMC6081589          DOI: 10.1155/2018/8285653

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


1. Introduction

Multiple sclerosis is one of the most common immune-mediated diseases involving central nervous system and presents the sex-specific rates of morbidity [1-3]. According to the report provided by Atlas of MS in 2013, the number of individuals affected by MS is about 2.3 million [4]. Previous Genome-wide association studies (GWAS) uncovered that about 200 variants in the human genome are associated with MS and they mainly affect immunological process related genes and lie in their regulatory regions [5, 6]. An immunoregulatory cytokine, macrophage migration inhibitory factor (MIF), plays an important role in the modulation of macrophages and microglia immune response and is associated with autoimmune and inflammation-related diseases including MS [7-11]. D-dopachrome tautomerase (DDT, also called MIF-2) is highly homologous to MIF and has a similar structure and functions as it [12-14]. Moreover, the promoter regions of MIF and DDT gene share sequences which contain some transcription factor binding sites [13, 14]. A recent study found that DDT is a sex-specific disease modifier for MS, and its high expression can promote MS progression in males but not females [15]. The single nucleotide polymorphism (SNP) rs755622 (G > C) lies in the promoter region of MIF, and previous studies showed that it is significantly associated with some immune-mediated diseases including MS [16, 17]. And then, this recent study further indicated a significant sex difference in the association between rs755622 polymorphism and MS [15]. Moreover, previous studies determined that rs755622 polymorphism affects the activity of MIF promoter and regulates MIF gene expression [18-20]. Given the relationship between MIF and DDT, we surmise that rs755622 polymorphism can also affect the expression of DDT. However, it is still unclear whether and how rs755622 polymorphism regulates DDT expression and the resulting impact on MS in different genders. Evidence showed that regulating gene expression is an important class of the biological functions of the genetic variants [21-30], and the expression quantitative trait loci (eQTL) analysis is an effective method to discover the correlations between genetic variants and quantitative changes in gene expression [21, 22, 24, 25, 27, 31–33]. Therefore, in this study, we first selected five large-scale expression quantitative trait loci (eQTLs) datasets to assess the potential influence of rs755622 variant on expression of DDT in normal brain tissues and blood by a linear regression analysis. And then, we further investigated how the rs755622 polymorphism affects DDT expression in brain and blood of the MS patients using two RNA-seq datasets. Finally, we performed the differential expression analysis of DDT between genders and explored whether there is a sex-specific regulation of DDT expression level by the rs755622 polymorphism.

2. Methods

2.1. eQTL Analysis Using Five Large-Scale Datasets

To validate the effect of rs755622 polymorphism on DDT expression level, we selected five large-scale eQTL datasets which primarily consist of the European ancestry individuals without MS diagnosis [34-38]. In particular, 10 brain regions (cerebellar cortex, frontal cortex, hippocampus, medulla, occipital cortex, putamen, substantia nigra, temporal cortex, thalamus, and intralobular white matter) of 134 individuals are included in Braineac [34]; 13 brain regions (amygdala, anterior cingulate cortex, caudate, cerebellar hemisphere, cerebellum, cortex, frontal cortex, hippocampus, hypothalamus, nucleus accumbens, putamen, spinal cord, and substantia nigra) of 1,497 individuals are included in GTEx [35]; the blood of 369, 2,765, 2,116, and 5,257 individuals is included in GTEx [35], CAGE [36], BIOS QTL Browser [37], and FHS_eQTL [38], respectively. Then, we selected the rs755622 genotype and DDT expression data from Braineac and conducted the eQTL analysis to assess the influence of rs755622 variant on expression of DDT by the R package ‘Matrix eQTL', which is based on a linear regression model with the parameters, gender and age, as the covariates [39]. Finally, we analyzed the eQTL results for rs755622 (including beta and P values) from the other four datasets.

2.2. eQTL Analysis of MS Subjects Using the RNA-Seq Data

To further investigate the regulation of DDT expression by rs755622 polymorphism in MS patients, we first selected the RNA-seq data from 2 GEO datasets, GSE100297 (single-end reads produced by the Illumina HiSeq 3000) [40], and GSE66573 (paired-end reads produced by the Illumina HiSeq 2500) [41], which include the brain (optic chiasm) and blood samples of 5 and 6 MS patients, respectively. We next mapped these sequences to human reference genome (hg19) and calculated the transcript per million (TPM) values to measure DDT expression level in each of the MS patients using the Kallisto software, which is a quantification tool of transcript abundance based on RNA-seq data [42]. Then, these RNA-seq data were reused to detect the genotype of rs755622 polymorphism in each of the MS patients. This process includes the following: (1) the sequence reads are aligned to reference genome (hg19) using BWA software with the default parameter settings [43] and (2) SNPs are called on these aligned reads using SAMtools software with the default parameter settings (100 read depth) [44]. For the called genotype of rs755622 polymorphism, a Hardy–Weinberg Equilibrium (HWE) test based on a noncontinuity correction chi-squared method with the significance level P < 0.05 was performed using the R package ‘Genetics' (https://cran.r-project.org/web/packages/genetics/index.html). Finally, we used the DDT expression and rs755622 polymorphism genotyping data of these MS patients to conduct the eQTL analysis by the R package ‘Matrix eQTL' [39] as described in the previous step.

2.3. Differential Expression Analysis of DDT between Genders

According to a recent study, Benedek et al. observed that DDT expression level is significantly higher in brain (white matter) of male MS subjects compared with female MS subjects [15]. However, previous studies reported that the sex-specific expression has already existed in many human genes, including some MS-related genes, for the normal individuals [45, 46]. Therefore, we further explored whether the sex-specific expression of DDT is a general genetic model for healthy people or associated with MS. Braineac database provided the DDT expression data of 10 brain regions from 134 individuals free of known neurological diseases with the age and age and gender details [34]. We used these data to detect if there is significantly different expression of DDT between genders in the normal individuals by Student's t-test (the significance level was set at P < 0.05).

2.4. Effect of rs755622 Polymorphism on DDT Expression Level in Different Gender

To further explore whether the effect of rs755622 polymorphism on DDT expression level has a sex-specific pattern, we selected the rs755622 polymorphism genotype data of 99 male and 35 female subjects from Braineac database [34], respectively. The HWE test of rs755622 polymorphism in male and female groups was performed, respectively, using the R package ‘Genetics' as described in the previous step. And then, we used Fisher's exact test to compare the genotype frequencies of rs755622 minor allele variant (C) between genders by the R program (http://www.r-project.org/). Finally, in combination with the DDT expression data in the 10 brain regions, we performed the eQTL analysis to assess the influence of rs755622 variant on expression of DDT in males and females, respectively, by the R package ‘Matrix eQTL' [39].

3. Results

3.1. eQTL Analysis Using Five Large-Scale Datasets

Using the large-scale eQTL data from Braineac, GTEx, CAGE, BIOS QTL Browser, and FHS_eQTL, we validated the effect of rs755622 polymorphism on DDT expression level. Interestingly, we found a significant association between rs755622 and DDT expression in brain (intralobular white matter, hippocampus, cerebellum, cerebellar hemisphere, and hypothalamus) and blood when the significance level was set at P < 0.05. In addition, we further found that the minor allele variant (C) of rs755622 can significantly upregulate DDT expression (β > 0) in all of these tissues. More detailed information is described in Table 1.
Table 1

Polymorphism rs755622 C allele upregulates DDT expression in brain and blood for subjects without MS diagnosis.

GeneSNPEffect alleleP valueEffect size (β)TissuesSample sizeDataset
DDT rs755622C1.47E-020.1282Brain intralobular white matter134Braineac
DDT rs755622C3.97E-020.1013Brain hippocampus134Braineac
DDT rs755622C1.66E-01-0.0874Brain cerebellar cortex134Braineac
DDT rs755622C5.84E-010.0284Brain frontal cortex134Braineac
DDT rs755622C3.61E-01-0.0436Brain medulla134Braineac
DDT rs755622C4.27E-01-0.0432Brain occipital cortex134Braineac
DDT rs755622C9.63E-01-0.0027Brain putamen134Braineac
DDT rs755622C2.09E-01-0.0630Brain substantia nigra134Braineac
DDT rs755622C6.74E-010.0219Brain temporal cortex134Braineac
DDT rs755622C3.87E-01-0.0462Brain thalamus134Braineac
DDT rs755622C5.09E-01-0.0743Brain amygdala88GTEx
DDT rs755622C3.28E-01-0.1050Brain anterior cingulate cortex109GTEx
DDT rs755622C8.55E-020.1732Brain caudate144GTEx
DDT rs755622C3.16E-010.1241Brain cortex136GTEx
DDT rs755622C1.61E-010.1353Brain frontal cortex118GTEx
DDT rs755622C7.21E-01-0.0383Brain hippocampus111GTEx
DDT rs755622C2.84E-010.1136Brain nucleus accumbens130GTEx
DDT rs755622C7.33E-01-0.0417Brain putamen111GTEx
DDT rs755622C1.24E-010.2706Brain spinal cord83GTEx
DDT rs755622C7.01E-01-0.0553Brain substantia nigra80GTEx
DDT rs755622C1.21E-040.5072Brain cerebellum154GTEx
DDT rs755622C1.21E-030.3480Brain cerebellar hemisphere125GTEx
DDT rs755622C2.91E-020.2388Brain hypothalamus108GTEx
DDT rs755622C4.62E-060.2260Blood369GTEx
DDT rs755622C3.70E-350.4214Blood2,765CAGE
DDT rs755622C4.31E-28> 0 (z =10.989)Blood2,116BIOS QTL Browser
DDT rs755622C5.21E-160.0427Blood5,257FHS_eQTL

The rs755622 position (hg19), 22_24236392_G_C_b37 (G > C); the threshold of significant association is 0.05; β > 0 and β < 0 means that this effect allele upregulates and downregulates gene expression, respectively; β = z × SE  (standard  errors); the asterisk (∗) means a significant association.

3.2. eQTL Analysis of MS Subjects Using the RNA-Seq Data

According to the Ensembl database, there are 7 transcripts for the gene DDT (ENST00000398344.8, ENST00000350608.7, ENST00000404092.5, ENST00000430101.2, ENST00000403754.7, ENST000004 28792.1, and ENST00000444947.2) [47]. We downloaded the sequences of these transcripts as reference and calculated their TPM values in the MS patients from 2 GEO datasets using the RNA-seq data and Kallisto software. We found that the expression levels of transcripts ENST00000350608.7 and ENST00000444947.2 are generally higher comparing with the other transcripts. These results are described in Supplementary Table S1 and Table S2. After the genotype calling of rs755622 polymorphism using these RNA-seq data, we found that there are 2 and 1 minor allele variants (C) of rs755622 in 2 MS patients from GSE100297 and GSE66573, respectively, and in other individuals no variant was detected at this polymorphism (Supplementary Table S3). And then, by setting the significance level at P < 0.05, we further observed that the genotype distribution of rs755622 polymorphism in the 2 groups of MS patients did not deviate from HWE (Supplementary Table S4). Next, we performed an eQTL analysis using expression level data of the 7 transcripts for gene DDT in combination with genotyping data of rs755622 polymorphism. The results show that the minor allele variant (C) of rs755622 can significantly upregulate the expression of transcript ENST00000444947.2 in blood and transcript ENST00000428792.1 both in brain (optic chiasm) and blood (P < 0.05 and β > 0), which is in accordance with the eQTL results of the individuals without MS as described in the previous step. More detailed information is summarized in Table 2.
Table 2

Polymorphism rs755622 C allele upregulates DDT expression in brain and blood for MS patients.

Transcript IDGeneSNPEffect alleleP valueEffect size (β)TissuesGEO dataset
ENST00000428792.1 DDT rs755622C2.23E-3086.72E+03Brain optic chiasmGSE100297
ENST00000428792.1 DDT rs755622C2.91E-153.60E+01BloodGSE66573
ENST00000444947.2 DDT rs755622C1.62E-021.23E+05BloodGSE66573

The rs755622 position (hg19), 22_24236392_G_C_b37 (G > C); the threshold of significant association is 0.05; β > 0 and β < 0 means that this effect allele upregulates and downregulates gene expression, respectively.

3.3. Differential Expression Analysis of DDT between Genders

To explore the association between sex-specific expression of DDT and MS, we compared the DDT expression levels between 134 males and females without known neurological diseases in 10 brain regions. The results of Student's t-test show that there is no significantly different expression of DDT between normal male and female individuals in all of the 10 brain regions (P < 0.05) (Figure 1). Combining Benedek et al.'s findings that DDT is significantly highly expressed in MS males compared to females in brain and its plasma concentration is closely related to the disease severity for MS males but not females [15], we further determined that sex-specific expression of DDT is associated with MS and affects the risk of MS for males.
Figure 1

Comparison of DDT expression level between healthy male and female subjects in brain. Sample size in these tissues: CRBL (cerebellar cortex): 35 females and 95 males; FCTX (frontal cortex): 34 females and 93 males; HIPP (hippocampus): 30 females and 92 males; MEDU (medulla): 31 females and 88 males; OCTX (occipital cortex): 35 females and 94 males; PUTM (putamen): 33 females and 96 males; SNIG (substantia nigra): 28 females and 73 males; TCTX (temporal cortex): 33 females and 86 males; THAL (thalamus): 33 females and 91 males; WHMT (intralobular white matter): 34 females and 97 males.

3.4. Effect of rs755622 Polymorphism on DDT Expression Level in Different Gender

Because the effect of DDT expression on risk of MS has a sex-specific pattern, we further explored whether the regulation of rs755622 polymorphism to DDT expression is also different in different gender. After the HWE test, the genotype distribution of rs755622 polymorphism did not deviate from HWE (P < 0.05) both in male and in female groups (Supplementary Table S4). By Fisher's exact test, the frequency of the rs755622 C-containing allele (GC/CC) is no significantly different between genders for healthy subjects (22.2%  vs.  22.9%, P = 1), while it is significantly higher in male MS subjects compared to female MS subjects according to the results of Benedek et al.'s study (42.6%  vs.  28.2%, P = 4.42 × 10−3) [34]. More detailed information is described in Supplementary Table S5. Finally, the results of eQTL analysis show that the minor allele variant (C) of rs755622 can significantly upregulate DDT expression for males but not females in intralobular white matter and hippocampus (P < 0.05 and β > 0). More detailed information is summarized in Table 3.
Table 3

Regulation of rs755622 polymorphism to DDT expression level in different gender.

GenderGeneSNPEffect alleleP valueEffect size (β)TissuesSample size
Female+Male DDT rs755622C 2.80E-02 1.29E-01Brain hippocampus122
Female DDT rs755622C1.05E-011.96E-01Brain hippocampus30
Male DDT rs755622C 4.41E-02 1.40E-01Brain hippocampus92
Female+Male DDT rs755622C 2.26E-02 1.24E-01Brain intralobular white matter131
Female DDT rs755622C3.14E-011.28E-01Brain intralobular white matter34
Male DDT rs755622C 2.03E-02 1.46E-01Brain intralobular white matter97

Significant associations (P < 0.05) marked in bold. The rs755622 position (hg19), 22_24236392_G_C_b37 (G > C); the threshold of significant association is 0.05; β > 0 and β < 0 means that this effect allele up-regulates and down-regulates gene expression, respectively.

4. Discussion

Both of MIF and DDT, which are highly homologous with each other, play an important role in the modulation of macrophages and microglia immune response [7, 8, 11–14]. Previous studies showed that both the MIF expression level and the variant of the rs755622 polymorphism in its promoter region are associated with MS progression [9, 10, 16, 17]. Moreover, other studies indicated that rs755622 polymorphism can regulate the expression of MIF gene by affecting the activity of its promoter [18-20]. Recently, Benedek et al. further found that DDT is a sex-specific disease modifier for MS [15]. Given the relationship between MIF and DDT, we surmise that rs755622 polymorphism may also sex-specifically affect the expression of DDT in MS. We first assessed the influence of rs755622 variant on the expression level of DDT in the normal subjects using five large-scale eQTL datasets [34-38]. And then, we further used two RNA-seq datasets to genotype the rs755622 polymorphism and performed the eQTL analysis to assess this effect in MS patients. Interestingly, the results show that the minor allele variant (C) of rs755622 can significantly up-regulate DDT expression level (P < 0.05 and β > 0) in brain tissues (intralobular white matter, hippocampus, cerebellum, cerebellar hemisphere, hypothalamus, and optic chiasm) and blood both for normal and MS subjects. The differential expression analysis shows that there is no significant difference in the expression level of DDT between the healthy male and female subjects. In combination with the results of Benedek et al.'s study [15], we further determined that the DDT is highly expressed in MS brain tissues and promotes MS progression for males but not females. Finally, by the eQTL analysis on male and female subjects using Braineac data [34], respectively, we found that the minor allele variant (C) of rs755622 can significantly upregulate DDT expression for males but not females. In addition, we also found that the distribution of the rs755622 polymorphism genotype is not significantly different between genders for healthy subjects, but the frequency of its minor allele variant (C) is significantly higher in male MS subjects according to Benedek et al.'s study [15]. Therefore, we think that both the rs755622 polymorphism sex-specific regulation and its different genotype distribution between genders in MS contribute to the high expression level of DDT in MS males. In summary, expression level of DDT is significantly high in male MS subjects comparing with females and closely related to the disease severity of MS in males [15]. There is a MS-related SNP rs755622 in the promoter region of MIF which is highly homologous to DDT, and the frequency of its minor allele variant (C) is significantly increased and associated with the high expression level of DDT in male MS subjects. These results indicate that the regulation of DDT expression level by the rs755622 polymorphism can affect MS progression in males, which further supports and expands the findings in previous studies [12-17] and may help to better understand the mechanisms of MS.
  47 in total

Review 1.  Multiple sclerosis--the plaque and its pathogenesis.

Authors:  Elliot M Frohman; Michael K Racke; Cedric S Raine
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

2.  Genetic variants regulate NR1H3 expression and contribute to multiple sclerosis risk.

Authors:  Yan Zhang; Longcai Wang; Haiyang Jia; Mingzhi Liao; Xiaoyun Chen; Jianyong Xu; Yunjuan Bao; Guiyou Liu
Journal:  J Neurol Sci       Date:  2018-04-22       Impact factor: 3.181

3.  Near-optimal probabilistic RNA-seq quantification.

Authors:  Nicolas L Bray; Harold Pimentel; Páll Melsted; Lior Pachter
Journal:  Nat Biotechnol       Date:  2016-04-04       Impact factor: 54.908

4.  Cell adhesion molecule pathway genes are regulated by cis-regulatory SNPs and show significantly altered expression in Alzheimer's disease brains.

Authors:  Xinjie Bao; Gengfeng Liu; Yongshuai Jiang; Qinghua Jiang; Mingzhi Liao; Rennan Feng; Liangcai Zhang; Guoda Ma; Shuyan Zhang; Zugen Chen; Bin Zhao; Renzhi Wang; Keshen Li; Guiyou Liu
Journal:  Neurobiol Aging       Date:  2015-06-12       Impact factor: 4.673

5.  MIF and D-DT are potential disease severity modifiers in male MS subjects.

Authors:  Gil Benedek; Roberto Meza-Romero; Kelley Jordan; Ying Zhang; Ha Nguyen; Gail Kent; Jia Li; Edwin Siu; Jenny Frazer; Marta Piecychna; Xin Du; Antoine Sreih; Lin Leng; Jack Wiedrick; Stacy J Caillier; Halina Offner; Jorge R Oksenberg; Vijayshree Yadav; Dennis Bourdette; Richard Bucala; Arthur A Vandenbark
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-18       Impact factor: 11.205

Review 6.  Genetics of Multiple Sclerosis: An Overview and New Directions.

Authors:  Nikolaos A Patsopoulos
Journal:  Cold Spring Harb Perspect Med       Date:  2018-07-02       Impact factor: 6.915

7.  The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia.

Authors:  Sachin Yende; Derek C Angus; Lan Kong; John A Kellum; Lisa Weissfeld; Robert Ferrell; David Finegold; Melinda Carter; Lin Leng; Zhi-Yong Peng; Richard Bucala
Journal:  FASEB J       Date:  2009-04-03       Impact factor: 5.191

8.  Defective structural RNA processing in relapsing-remitting multiple sclerosis.

Authors:  Charles F Spurlock; John T Tossberg; Yan Guo; Subramaniam Sriram; Philip S Crooke; Thomas M Aune
Journal:  Genome Biol       Date:  2015-03-25       Impact factor: 13.583

9.  Ensembl 2017.

Authors:  Bronwen L Aken; Premanand Achuthan; Wasiu Akanni; M Ridwan Amode; Friederike Bernsdorff; Jyothish Bhai; Konstantinos Billis; Denise Carvalho-Silva; Carla Cummins; Peter Clapham; Laurent Gil; Carlos García Girón; Leo Gordon; Thibaut Hourlier; Sarah E Hunt; Sophie H Janacek; Thomas Juettemann; Stephen Keenan; Matthew R Laird; Ilias Lavidas; Thomas Maurel; William McLaren; Benjamin Moore; Daniel N Murphy; Rishi Nag; Victoria Newman; Michael Nuhn; Chuang Kee Ong; Anne Parker; Mateus Patricio; Harpreet Singh Riat; Daniel Sheppard; Helen Sparrow; Kieron Taylor; Anja Thormann; Alessandro Vullo; Brandon Walts; Steven P Wilder; Amonida Zadissa; Myrto Kostadima; Fergal J Martin; Matthieu Muffato; Emily Perry; Magali Ruffier; Daniel M Staines; Stephen J Trevanion; Fiona Cunningham; Andrew Yates; Daniel R Zerbino; Paul Flicek
Journal:  Nucleic Acids Res       Date:  2016-11-28       Impact factor: 16.971

10.  Genetic variability in the regulation of gene expression in ten regions of the human brain.

Authors:  Adaikalavan Ramasamy; Daniah Trabzuni; Sebastian Guelfi; Vibin Varghese; Colin Smith; Robert Walker; Tisham De; Lachlan Coin; Rohan de Silva; Mark R Cookson; Andrew B Singleton; John Hardy; Mina Ryten; Michael E Weale
Journal:  Nat Neurosci       Date:  2014-08-31       Impact factor: 24.884

View more
  5 in total

1.  Brief report: Enhanced DRα1-mMOG-35-55 treatment of severe EAE in MIF-1-deficient male mice.

Authors:  Arthur A Vandenbark; Roberto Meza-Romero; Jack Wiedrick; Grant Gerstner; Ashley Headrick; Gail Kent; Hilary Seifert; Gil Benedek; Richard Bucala; Halina Offner
Journal:  Cell Immunol       Date:  2021-09-11       Impact factor: 4.868

2.  A Polymorphism Within the MBP Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple Sclerosis.

Authors:  Laura Espino-Paisán; Teresa Agudo-Jiménez; Isabel Rosales-Martínez; Pilar López-Cotarelo; María Ángel García-Martínez; María Inmaculada Domínguez-Mozo; Silvia Pérez-Pérez; Romina Dieli-Crimi; Manuel Comabella; Elena Urcelay; Roberto Álvarez-Lafuente
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

3.  Genetic Variants of the MIF Gene and Susceptibility of Rectal Cancer.

Authors:  Dongyu Chuo; Dapeng Lin; Mingdi Yin; Yuze Chen
Journal:  Pharmgenomics Pers Med       Date:  2021-01-12

4.  Upregulated Expression of Macrophage Migration Inhibitory Factor, Its Analogue D-Dopachrome Tautomerase, and the CD44 Receptor in Peripheral CD4 T Cells from Clinically Isolated Syndrome Patients with Rapid Conversion to Clinical Defined Multiple Sclerosis.

Authors:  Eugenio Cavalli; Emanuela Mazzon; Maria Sofia Basile; Katia Mangano; Roberto Di Marco; Placido Bramanti; Ferdinando Nicoletti; Paolo Fagone; Maria Cristina Petralia
Journal:  Medicina (Kaunas)       Date:  2019-10-01       Impact factor: 2.430

5.  Integrating the Ribonucleic Acid Sequencing Data From Various Studies for Exploring the Multiple Sclerosis-Related Long Noncoding Ribonucleic Acids and Their Functions.

Authors:  Zhijie Han; Jiao Hua; Weiwei Xue; Feng Zhu
Journal:  Front Genet       Date:  2019-11-12       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.